Literature DB >> 15963538

The dopamine D3 receptor and drug dependence: effects on reward or beyond?

Bernard Le Foll1, Steven R Goldberg, Pierre Sokoloff.   

Abstract

Abused drugs (alcohol, heroin, cocaine, tetrahydrocannabinol and nicotine) elicit a variety of chronically relapsing disorders by interacting with brain reward systems. All of these drugs increase dopamine levels in the shell of nucleus accumbens, a structure that has been involved in their hedonic and reinforcing properties. Dopamine D(3) receptors (DRD3) are predominantly expressed in the nucleus accumbens, but also in the ventral tegmental area and in the amygdala, brain structures implicated in drug dependence. Moreover, converging pharmacological, human post-mortem and genetic studies have suggested the involvement of the DRD3 in drug dependence. Based on early studies using non-selective DRD3 ligands, the DRD3 was proposed as having a direct role in the rewarding effects of psychostimulants. However, recent studies using highly selective DRD3 ligands and the DRD3-deficient mice have revealed that the DRD3 is not implicated in the direct reinforcing effects of drugs of abuse. In contrast, the DRD3 appears to be implicated in the motivation to self-administer drugs under schedules where the response requirements are high. This is consistent with a behavioral economic analysis, with the effects of DRD3 ligands revealed only in situations with high prices for drug. Drug-self administration and relapse are strongly controlled by environmental stimuli. The DRD3 strongly modulates the influence of these environmental stimuli on drug-seeking behavior. DRD3 blockade disrupts the reactivity to drug-associated stimuli in various paradigms, such as second-order schedules of drug-self administration, conditioned place preference and Pavlovian conditioning procedures. In several paradigms, the involvement of the DRD3 has been confirmed by using DRD3-deficient mice. On the contrary, reactivity to stimuli associated with natural reinforcers, such as food, appears unaffected by modulation of the DRD3. All these findings suggest that DRD3 ligands may represent a useful strategy for decreasing relapse in abstinent drug-abusers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15963538     DOI: 10.1016/j.neuropharm.2005.04.022

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  76 in total

1.  The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access.

Authors:  Laura Orio; Sunmee Wee; Amy H Newman; Luigi Pulvirenti; George F Koob
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

2.  Dopamine D3-like receptors modulate anxiety-like behavior and regulate GABAergic transmission in the rat lateral/basolateral amygdala.

Authors:  Marvin R Diaz; Ann M Chappell; Daniel T Christian; Nancy J Anderson; Brian A McCool
Journal:  Neuropsychopharmacology       Date:  2011-01-26       Impact factor: 7.853

3.  Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers.

Authors:  David Matuskey; Patrick Worhunksy; Elizabeth Correa; Brian Pittman; Jean-Dominique Gallezot; Nabeel Nabulsi; Jim Ropchan; Venkatesh Sreeram; Rohit Gudepu; Edward Gaiser; Kelly Cosgrove; Yu-Shin Ding; Marc N Potenza; Yiyun Huang; Robert T Malison; Richard E Carson
Journal:  Neuroimage       Date:  2016-02-11       Impact factor: 6.556

4.  Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study.

Authors:  Isabelle Boileau; Doris Payer; Sylvain Houle; Arian Behzadi; Pablo M Rusjan; Junchao Tong; Diana Wilkins; Peter Selby; Tony P George; Martin Zack; Yoshiaki Furukawa; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

5.  The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.

Authors:  Arlene C Pak; Charles R Ashby; Christian A Heidbreder; Maria Pilla; Jeremy Gilbert; Zheng-Xiong Xi; Eliot L Gardner
Journal:  Int J Neuropsychopharmacol       Date:  2006-08-31       Impact factor: 5.176

6.  Influence of cocaine history on the behavioral effects of Dopamine D(3) receptor-selective compounds in monkeys.

Authors:  B L Blaylock; R W Gould; A Banala; P Grundt; R R Luedtke; A H Newman; M A Nader
Journal:  Neuropsychopharmacology       Date:  2011-02-02       Impact factor: 7.853

Review 7.  [Future medications for tobacco and cannabis dependence].

Authors:  Bernard Le Foll; Zuzana Justinova; Gianlugi Tanda; Steven R Goldberg
Journal:  Bull Acad Natl Med       Date:  2008-01       Impact factor: 0.144

8.  Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors.

Authors:  J Robert Lane; Pavel Chubukov; Wei Liu; Meritxell Canals; Vadim Cherezov; Ruben Abagyan; Raymond C Stevens; Vsevolod Katritch
Journal:  Mol Pharmacol       Date:  2013-09-10       Impact factor: 4.436

9.  Reduction of cocaine self-administration and D3 receptor-mediated behavior by two novel dopamine D3 receptor-selective partial agonists, OS-3-106 and WW-III-55.

Authors:  Timothy H C Cheung; Amy L Loriaux; Suzanne M Weber; Kayla N Chandler; Jeffrey D Lenz; Romina F Schaan; Robert H Mach; Robert R Luedtke; Janet L Neisewander
Journal:  J Pharmacol Exp Ther       Date:  2013-09-09       Impact factor: 4.030

Review 10.  Heterogeneity of reward mechanisms.

Authors:  A Lajtha; H Sershen
Journal:  Neurochem Res       Date:  2009-12-12       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.